252 0 Kommentare Dynavax Announces Presentation of Clinical Data at ASH Annual Meeting

BERKELEY, CA--(Marketwired - Nov 30, 2015) - Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it will present clinical data at the 57^th American Society of Hematology (ASH) Annual Meeting this weekend in Orlando, Florida. The details for the poster presentation are as follows:

Date and Time: Saturday, December 5, 2015, 5:30pm - 7:30pm EST
Abstract Title: Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN.
Session Number: 616
Session Name: Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster I
Abstract Number: 1539
Location: Hall A, Level 2 (Orange County Convention Center)

Long

120,88€

Basispreis

0,96

Ask

× 11,04

Hebel

Zum Produkt

Short

144,24€

Basispreis

1,27

Ask

× 8,35

Hebel

Zum Produkt

Präsentiert von

Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

Please click here for the full abstract. The poster presentation with updated data will be made available on or after December 5, 2015.

About SD-101

SD-101, the subject of ASH abstract 1539, is Dynavax's proprietary, second-generation, TLR 9 agonist CpG-C class oligodeoxynucleotide. SD-101 activates multiple anti-tumor activities of innate immune cells and activates plasmacytoid dendritic cells to stimulate T cells specific for antigens released from dying tumor cells. TLR9 agonists such as SD-101 enhance T and B cell responses and provide potent Type 1 interferon induction and maturation of plasmacytoid dendritic cells to antigen-presenting cells. SD-101 is being evaluated in several Phase 1/2 oncology studies to assess its preliminary safety and activity.

About Dynavax

Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidates are HEPLISAV-B™, a Phase 3 investigational adult hepatitis B vaccine and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information, visit www.dynavax.com.

Contact:
Michael Ostrach
Chief Financial Officer
510-665-7257
Email Contact